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Proton Rahman11, Dafna D. Gladman12, AnneM. Bowcock13, Cynthia Helms13, Gerald G. Krueger14, Sulev Koks15,
Ku¨lli Kingo16, Christian Gieger17, H. Erich Wichmann18,19,20, Ulrich Mrowietz21, Stephan Weidinger21,
Stefan Schreiber1,22, Gonc¸alo R. Abecasis6, James T. Elder2,23, Michael Weichenthal21 and Andre Franke1
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease affecting up to 30% of psoriasis vulgaris
(PsV) cases and approximately 0.25 to 1% of the general population. To identify common susceptibility loci, we
performed a meta-analysis of three imputed genome-wide association studies (GWAS) on psoriasis, stratified for
PsA. A total of 1,160,703 single-nucleotide polymorphisms (SNPs) were analyzed in the discovery set consisting of
535 PsA cases and 3,432 controls from Germany, the United States, and Canada. We followed up two SNPs in 1,931
PsA cases and 6,785 controls comprising six independent replication panels from Germany, Estonia, the
United States, and Canada. In the combined analysis, a genome-wide significant association was detected at 2p16
near the REL locus encoding c-Rel (rs13017599, P¼ 1.18 108, odds ratio (OR)¼ 1.27, 95% confidence interval
(CI)¼ 1.18–1.35). The rs13017599 polymorphism is known to associate with rheumatoid arthritis (RA), and another
SNP near REL (rs702873) was recently implicated in PsV susceptibility. However, conditional analysis indicated that
rs13017599, rather than rs702873, accounts for the PsA association at REL. We hypothesize that c-Rel, as a member of
the Rel/NF-kB family, is associated with PsA in the context of disease pathways that involve other identified PsA and
PsV susceptibility genes including TNIP1, TNFAIP3, and NFkBIA.
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INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory musculo-
skeletal disease that occurs in the context of psoriasis vulgaris
(PsV) affecting up to 30% of psoriasis patients (Gladman
et al., 2005). Apart from the skin manifestation of PsV, the
clinical phenotype of PsA overlaps with ankylosing spondy-
litis and rheumatoid arthritis (RA) (Castelino and Barton,
2010). Although PsV has a prevalence of up to 3% in
populations of European ancestry (Bowcock and Barker,
2003; Griffiths and Barker, 2007), the estimated prevalence
of PsA varies from 0.25 to 1% (Gladman et al., 2005). The
strong genetic component of PsA is evidenced by the high
sibling recurrence risk (lS) of 27–47 (Gladman et al., 2003;
Myers et al., 2005; Chandran et al., 2009), which is much
higher than the estimated lS¼4–11 of PsV (Elder et al., 1994;
Bhalerao and Bowcock, 1998), suggesting that PsA patients
harbor additional susceptibility loci beside the loci that
contribute to risk for PsV. In addition to the significant
heritable component, environmental risk factors have an
important role for both PsV and PsA. The onset of PsA
generally occurs in the fourth and fifth decades of life. In
nearly 80% of patients, the skin disease (PsV) precedes the
arthritis (PsA). The clarification of similarities and differences
of the genetic background in PsV and PsA offers chances for
well-targeted interventions, i.e., specific therapies for both
conditions. It would also provide an opportunity to identify
PsV patients with increased risk of PsA and would allow
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treatment at the earliest signs of joint involvement (Bowes
and Barton, 2010).
Several susceptibility loci for PsV have been identified
with genome-wide levels of statistical significance in
populations of European origin, including HLA-Cw6, IL12B,
IL23R, IL4-IL13, IL23A, TNIP1, TNFAIP3, LCE3B-LCE3C,
RNF114, TRAF3IP2, NFkBIA, NOS2, FBXL19, TYK2, IFIH1,
REL, IL28RA, and ERAP1 (Liu et al., 2008; Duffin et al., 2010;
Ellinghaus et al., 2010; Strange et al., 2010; Stuart et al.,
2010). Many of the susceptibility loci for PsV tested so far are
also genome-wide significantly associated with PsA such as
HLA-Cw6, IL12B, TNIP1, FBXL19, and TRAF3IP2 or at the
level of Po0.05 such as IL23R, IL23A, TNFAIP3, NFkBIA,
NOS2, and IL13 (Bowes and Barton, 2010; Ellinghaus et al.,
2010; Huffmeier et al., 2010; Stuart et al., 2010; Eder et al.,
2011). However, because the causative allele(s) have not
been identified within most of these regions, their actual
contribution to disease risk remains unknown.
To further our understanding of PsA etiology, we
conducted a meta-analysis of the PsA subsets of three
independent genome-wide association studies (GWAS) of
PsV from Kiel, Germany (Ellinghaus et al., 2010), the
Collaborative Association Study of Psoriasis (CASP; Nair
et al., 2009) and Canada (Genizon, unpublished data),
consisting of 535 PsA patients and 3,432 healthy controls.
Genotype imputation with HapMap phase 3 reference
samples considerably increased the genomic coverage of
the three GWAS data sets and facilitated the combined
analysis. For replication, we selected 10 single nucleotide
polymorphisms (SNPs) based on their P-value ranking in the
meta-analysis and genotyped them in two independent
replication sets from Germany and Estonia. The two most
strongly associated SNPs were further genotyped in four
additional replication cohorts from Michigan, the National
Psoriasis Foundation, the CASP Deep Follow-up (CASP-
DFU), and Estonia. Together, this replication set comprised
1,931 PsA cases and 6,785 controls (Supplementary Table S1
online). We identified genome-wide significant association
for SNP rs13017599, which is located between the genes REL
and PUS10, and has been already reported to be associated
with RA (Gregersen et al., 2009). Our results indicate that REL
is an important candidate susceptibility locus not only for PsV
and RA but also for PsA.
RESULTS
Before genotype imputation and meta-analysis, we applied
extensive quality control filters to the three GWAS data sets
separately. We excluded all samples with low genotyping
rate (o95%), as well as non-European outliers or cryptically
related individuals. Further, we excluded SNPs with a minor
allele frequency o1%, a genotyping success rate o95%, or
deviation of the genotype distribution from Hardy–Weinberg
equilibrium (HWE) in the controls (Po104). After applying
these stringent quality control filters, genotype imputation
was performed with Beagle v.3.2.1 (Browning and Browning,
2009) using HapMap phase 3 reference haplotypes (Altshuler
et al., 2010). Only SNPs imputed with high confidence
(estimated r2 between imputed and true genotypesX0.3) in
all three GWAS were considered for subsequent statistical
analysis, leaving a total of 1,160,703 SNPs. A logistic
regression procedure was applied to test both genotyped
and imputed SNPs for association. To account for uncertainty
in the imputation procedure, we used allele dosages from the
imputation. After combining the association results of all
three scans, a low genomic-control value (meta GWAS:
lGC¼ 1.02) indicated a minimal overall inflation of the
test statistics due to population stratification (Supplemen-
tary Figure S1 online). Our combined discovery panel had
80% power to detect variants conferring odds ratios (ORs) of
1.40 or higher at the 5% significance level, assuming a
frequency of the disease-associated risk allele of at least 15%
in controls (Supplementary Figure S2 online). In line with
previous studies, we detected the strongest associations
with PsA at SNPs in the HLA complex at chromosome
6p21 approximately 35 kb upstream of HLA-C (rs12212594,
P¼4.98 1038, OR¼3.60; rs12191877, P¼3.95 1035,
OR¼2.73; and rs10484554, P¼3.03 1034, OR¼2.72;
Manhattan plot see Figure 1). SNP rs12191877 was previ-
ously identified as most strongly associated with PsV in a
GWAS of individuals with genuine European ancestry (Nair
et al., 2009), whereas rs10484554 has been described to be
most significantly associated in a combined study of PsA and
PsV (Liu et al., 2008). In our discovery panel, rs12212594
was in moderate linkage disequilibrium with rs12191877
(r2¼ 0.57), indicating that these signals are not independent.
In addition, we found evidence of association at the previ-
ously reported susceptibility loci TNIP1 (Nair et al., 2009;
rs17728338, P¼6.751010, OR¼2.07) and IL12B (Liu
et al., 2008; rs3212227, P¼3.82 107, OR¼1.64). For
selection of follow-up SNPs, we excluded all SNPs within the
extended major histocompatibility complex region (7,773
SNPs on chromosome 6 at 25–34Mb), as well as SNPs within
the genes TNIP1 and IL12B, as these loci have already been
shown to be associated with PsA at a genome-wide
significant level. Furthermore, we used only those SNPs that
were available in all three scans, and that showed no
heterogeneity between the studies (I2 statistic¼ 0). We
selected 10 SNPs for replication (see Manhattan plot, Figure 1)
in two independent samples from Germany and Estonia
(replication panels 1 and 2) comprising 252 PsA cases and
1,740 controls. All SNPs passed quality control measures,
which means that they had a high call rate (495% in cases or
controls), were not monomorphic (minor allele frequency
41% in cases or controls), and did not deviate from the HWE
in the control population (P-value4104). Taking into
account the minor differing genetic backgrounds of the two
replication study groups, we used the Cochran–Mantel–-
Haenszel test for the combined analysis (Table 1). Of the 10
follow-up SNPs, 2 SNPs were nominally associated with PsA
in the replication data set (rs13017599 and rs2829866 with
Po0.05) and were therefore genotyped in four additional
replication panels from Michigan, the National Psoriasis
Foundation, the CASP-DFU, and Estonia (replication panels 3
through 6), yielding a replication sample consisting of 1,931
PsA cases and 6,785 controls. In the combined replication
analysis, rs13017599—located 15 kb downstream of REL and
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5 kb downstream of PUS10—remained significantly asso-
ciated with PsA, yielding P¼4.24105 (OR¼1.23, 95%
confidence interval (CI)¼1.14–1.33, no heterogeneity:
I2¼ 0). In contrast, rs2829866 showed no evidence for
association in the extended replication sample (a¼0.005,
calculated as 0.05/10). The combined analysis of the
discovery and the six replication panels (2,466 PsA cases
and 10,217 controls) yielded a genome-wide significant
P-value of 1.18108 (OR¼ 1.27, 95% CI¼1.18–1.35,
I2¼ 0) for the lead SNP rs13017599 (Table 2). To fine map
a region of 500 kb around the lead SNP rs13017599, we
performed imputation based on CEU haplotypes generated by
the 1000 Genomes Project for the three GWAS panels used
for discovery phase (The 1000 Genomes Project Consortium,
2010). The regional plot of the combined P-values confirmed
the results of the HapMap phase 3-imputed meta-analysis,
with rs13017599 displaying the strongest association
(P¼1.88105) at this locus (Figure 2). In addition, we
genotyped the SNP rs702873, which was reported to be
associated with PsV by Strange et al. (2010) in the replication
panels 1 through 6 (1,931 PsA cases and 6,785 controls).
Meta-analysis of the three GWAS and the six replication
study groups (2,466 PsA cases and 10,217 controls) yielded
P¼1.93 107 (OR¼ 1.20, 95% CI¼1.13–1.28), confirm-
ing the newly identified association of this locus with PsA
(Tables 1 and 2). The lead SNP rs13017599 and the PsV-
associated variant rs702873 are about 83 kb apart and are in
moderate linkage disequilibrium (linkage disequilibrium in
566 CEU haplotypes generated by the 1000 Genomes Project
(The 1000 Genomes Project Consortium, 2010); r2¼0.625).
To test for the independence of these two markers, we
performed a logistic regression analysis. When conditioning
for the lead SNP rs13017599, rs702873 was not significantly
associated with PsA (P¼ 0.20), whereas rs13017599 was still
associated (P¼2.90 102) in the reverse conditioning,
indicating that the two SNPs are not completely independent,
but that rs13017599 accounts for the association of PsA at the
REL gene locus rather than rs702873. To investigate whether
the REL locus was more strongly associated with PsA than
with PsV, we additionally analyzed the two REL SNPs
rs13017599 and rs702873 in PsV cases without PsA from
the same three GWAS and six replication panels (5,912 PsV
cases without PsA and 10,217 controls). This analysis yielded
much weaker association signals compared with the PsA
cohort (rs13017599, PPsV¼3.48 105, OR¼ 1.13, 95%
CI¼1.08–1.19; rs702873, PPsV¼4.70 106, OR¼1.14,
95% CI¼ 1.09–1.19), highlighting that the REL association
is stronger in PsA, but nevertheless confirming the previ-
ously reported association of rs702873 with PsV. For each
of the two associations at rs13017599 and rs702873, there is
an overlap in CIs for PsA and PsV, which further proves
that the REL gene represents a shared susceptibility locus for
PsA and PsV.
DISCUSSION
In addition to the recently reported association of SNP
rs13017599 with RA (Gregersen et al., 2009) and SNP
rs702873—located 27 kb upstream of the REL gene—with
PsV (Strange et al., 2010), several other SNPs downstream of
REL have been identified to be associated with ulcerative
colitis (McGovern et al., 2010), Crohn’s disease (Franke et al.,
2010), celiac disease (Dubois et al., 2010), and primary
sclerosing cholangitis (Janse et al., 2011), demonstrating that
REL is a shared disease locus of several complex diseases and
thereby highlighting its role in inflammatory barrier disease
susceptibility. REL encodes one of four subunits found in
NF-kB dimers and belongs to the NF-kB (REL) family of
transcription factors, which is highly important in the innate
immune system. The above-mentioned association findings
are therefore consistent with the importance of the NF-kB
pathway in these inflammatory diseases. c-Rel contains
trans-activation domains that are a prerequisite for gene
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Figure 1. Results of genome-wide meta-analysis. The negative decadic logarithm of the corresponding P-value from the meta-analysis is shown for each
single-nucleotide polymorphism (SNP), according to chromosome. All markers that passed quality control criteria, those that were available in all three
genome-wide association studies (GWAS), and those that showed no heterogeneity between the studies were used for plotting. The plot was created with
the software environment R version 2.11.1 (Team, 2007). The established PsA loci HLA-C and TNIP1 are highlighted by gray arrows, whereas the follow-up
loci are tagged by black arrows. The novel risk locus at REL is highlighted by a red arrow. TheHLA region stands out clearly from all other loci. For better scaling,
the y axis was limited to a maximum value of log10(P-value)¼ 10, thereby truncating the HLA signal at this value.
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transcription, and T-cell–mediated immune responses were
markedly impaired in c-Rel/ animals. The confirmed PsA/
PsV susceptibility locus TNFAIP3 and a variety of other genes
are regulated by c-Rel in T cells (Bunting et al., 2007).
Notably, c-REL mediates differentiation of CD4þ FoxP3þ
regulatory T cells, which have the capacity to develop into
IL-17-producing cells in psoriasis (Bovenschen et al., 2011). It
also promotes IL-12B and IL-23 expression, by which TH-1
and TH-17 types of immune response might be evoked (Mise-
Omata et al., 2007; Reinhard et al., 2011). Altogether, these
findings further support the hypothesis that REL is an
important integrator of inflammatory signaling pathways
observed in the complex emerging landscape of genetic
susceptibility for PsA.
In conclusion, we were able to provide—to our knowl-
edge previously unreported—genome-wide significant evi-
dence for involvement of the REL locus in PsA susceptibility,
and we could confirm the previously reported association
with PsV. The current results demand not only a thorough
analysis of all genes involved in this pathway to search for
additional risk alleles but also overlap analyses between
complex disorders sharing a certain genetic background,
such as PsA, PsV, and RA. It should be noted, however, that
because most of the patients develop PsA following the onset
of PsV, PsA might be considered as a disease within a disease
with psoriasis as the parent disease (Eder et al., 2011), so that
any association study on PsA is bound to identify PsV
susceptibility genes such as the established PsV/PsA risk loci
HLA-Cw6, IL12B, IL23R, TNIP1, and FBXL19, which do not
allow for genetic discrimination between the two conditions.
On the other hand, the genetic component of PsA is much
higher than that of PsV, and only about one-third of PsV
patients additionally develop PsA, implying that differences
in the genetic backgrounds do exist. Genes involved in innate
(such as REL) and adaptive immunity are expectedly more
often shared between different immune-mediated diseases,
whereas genes of skin barrier function are rather restricted to
PsV. So far, no PsA-specific associations have been identified
with genome-wide significance. Lack of power to find genetic
variants with weaker effects, and rare variants that contribute
Table 1. Association results of ten follow-up SNPs from the meta-analysis and of the PsV-associated SNP rs702873
Genome-wide analysis
(535 cases, 3,432 controls) Replication analysis (252 PsA cases, 1,740 controls)
Combined analysis
(GWAS, Repl. 1+2)
(787 PsA cases,
5,172 controls)
Allele frequencies
(ca/co) Repl. 1+2
Locus SNP
Chromosome
position (bp) Alleles
Meta
P-value
OR
(95% CI)
Repl. 1
Germany
Repl. 2
Estonia 1 PCMH
OR
(95% CI) PBD
Meta
P-value OR
STXBP4/
HLF
rs171511 17
53,273,910
T/C 9.30 106 1.37 (1.19–1.58) 0.39/0.36 0.42/0.44 0.59 1.06 (0.87–1.29) 0.33 8.62105 1.26
RAD50 rs6596086 5
131,952,222
T/C 9.77 106 1.51 (1.26–1.81) 0.77/0.75 0.71/0.67 0.26 1.14 (0.91–1.42) 0.77 3.52105 1.35
REL/PUS10 rs13017599 2
61,164,331
G/A 1.48 105 1.37 (1.19–1.57) 0.69/0.62 0.67/0.63 8.92 103 1.31 (1.07–1.61) 0.63 4.56107 1.35
PTDSS1 rs7824505 8
97,330,691
A/C 1.49 105 1.37 (1.19–1.57) 0.49/0.47 0.39/0.48 0.48 0.93 (0.77–1.13) 0.04 2.00103 1.20
CCDC65 rs10783293 12
49,308,475
A/G 1.83 105 1.34 (1.17–1.53) 0.43/0.44 0.43/0.43 0.68 0.96 (0.79–1.17) 0.80 9.95104 1.20
A2BP1 rs12445208 16
7,325,638
A/C 3.72 105 1.48 (1.23–1.78) 0.80/0.81 0.83/0.81 0.99 1.00 (0.78–1.28) 0.51 1.10103 1.28
IL5RA rs3792424 3
3,117,700
A/G 3.97 105 1.94 (1.42–2.67) 0.91/0.93 0.93/0.91 0.99 1.00 (0.69–1.43) 0.18 2.98103 1.43
MARCH1 rs7686154 4
164,542,625
T/G 6.56 105 2.83 (1.70–4.71) 0.96/0.96 0.92/0.93 0.95 0.99 (0.63–1.54) 0.53 1.08102 1.55
CCR6/
FGFR1OP
rs162295 6
167,454,097
A/C 8.62 105 1.36 (1.17–1.59) 0.72/0.73 0.70/0.67 0.88 1.02 (0.82–1.26) 0.37 1.14103 1.23
JAM2 rs2829866 21
27,059,071
A/T 1.00 104 1.32 (1.15–1.52) 0.37/0.30 0.27/0.25 3.75 102 1.24 (1.01–1.53) 0.39 1.14105 1.30
PAPOLG/
REL
rs702873 2
61,081,542
C/T 1.56 104 1.29 (1.13–1.48) 0.61/0.56 0.63/0.57 3.38 102 1.24 (1.02–1.50) 0.77 1.57105 1.28
Abbreviations: CI, confidence interval; CMH, Cochran–Mantel–Haenszel test; GWAS, genome-wide association study; OR, odds ratio; PBD, asymptotic
PBD-value of the Breslow–Day test for heterogeneity; PsA, psoriatic arthritis; PsV, psoriasis vulgaris; Repl, replication; SNP, single-nucleotide polymorphism.
The top 10 SNPs that were selected for follow-up from the meta-analysis are listed. These SNPs were genotyped in the replication case–control panel 1
and 2 from Germany and Estonia, respectively. Moreover, we genotyped the SNP rs702873 that was previously reported to be associated with PsV (Strange
et al., 2010). SNPs are ranked according to their P-values obtained in the initial meta-analysis. Positions (Position (bp)) are in NCBI’s build 37. A significant
PBD-value indicates a significant heterogeneity between the two replication panels in terms of the odds ratio of the disease association. Combined P-values
(PCMH) and combined ORs of the CMH test statistic (one degree of freedom) are shown for replication panels 1 and 2. Significant P-values (PCMHo0.05 (only
if PBD40.05)) of the replication panels are highlighted in bold.
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to disease risk, might explain the sparse results, thereby
emphasizing the need for larger studies and targeted next-
generation sequencing of candidate regions.
MATERIALS AND METHODS
Subjects
All German PsA (219) and PsV (733) cases in the GWAS panel and in
the replication panel 1 were recruited either at the Department of
Dermatology of the Christian-Albrechts-University Kiel or at the
Department of Dermatology and Allergy of the Technical University
Munich through local outpatient services. PsA was diagnosed by a
clinical finding of joint complaints and radiological and rheumato-
logical confirmation of criteria according to Moll and Wright (1973),
or, more recently, to the Classification Criteria for Psoriatic Arthritis
(CASPAR; Taylor et al., 2006). In all, 63 PsA cases from Munich were
diagnosed by a physician, with negative diagnosis of RA. Individuals
were considered to be affected by PsV if chronic plaque or guttate
psoriasis lesions covered more than 1% of the total body surface area
or if at least two skin, scalp, nail, or joint lesions were clinically
diagnosed as characteristic of psoriasis by a dermatologist.
In all, 2,127 German healthy control individuals in the GWAS
panel and the replication panel 1 were obtained from the PopGen
biobank (Krawczak et al., 2006). A total of 465 German healthy
controls were selected from the KORA S4 survey, an independent
population-based sample from the general population living in the
region of Augsburg, southern Germany (Wichmann et al., 2005).
The CASP GWAS (for details see (Nair et al., 2009; Stuart et al.,
2010)) consisted of 335 PsA cases, 915 PsV cases, and 1,322 controls
after quality control measures. The data sets used for the analyses
described in this manuscript were obtained from the database of
Genotype and Phenotype (http://www.ncbi.nlm.nih.gov/gap).
The Canadian GWAS sample (from Genizon BioSciences,
St Laurent, Quebec, Canada) consisted of 139 PsA cases, 614 PsV
cases, and 987 controls sampled from the Que´bec founder popula-
tion. Membership in the Que´bec founder population was defined as
having four grandparents with French–Canadian family names who
were born in the Province of Que´bec, Canada, or in adjacent areas
in the provinces of New Brunswick and Ontario, or in New England
or New York State. This criterion assured that all subjects were
descendants of French Canadians living before the 1960s, after
which time admixture with non-French Canadians became more
common. Inclusion criteria were the presence of plaque-forming
psoriasis determined by a dermatologist, and disease onset between
18 and 40 years of age. Exclusion criteria were other forms of
psoriasis, such as pustular, guttate, inverse, erythrodermic, and
isolated site psoriasis and late onset. The presence of PsA was noted,
but was not an ascertainment criterion.
The samples of the Estonian replication panel 2 were unrelated
Estonian Caucasian patients with a clear clinical diagnosis of PsV,
collected at the Department of Dermatology and Venerology and at
the Department of Physiology and Centre of Translational Medicine
at the University of Tartu. Patients were classified as having PsA if
this diagnosis had been established by an experienced rheumatol-
ogist. The Estonian replication panel 6 consisted of samples provided
by the population-based biobank of the Estonian Genome Center,
University of Tartu. Subjects were recruited by general practitioners
and physicians in the hospitals. Physicians in the hospitals were
randomly selected from individuals visiting general practitioner
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offices or hospitals. Diagnosis of PsV and/or PsA based on clinical
symptoms was posed by a general practitioner and confirmed by a
dermatologist. At the time of recruitment, the controls did not report
diagnosis of osteoarthritis, psoriasis, or autoimmune diseases.
Replication panels 3 through 5 (Michigan, National Psoriasis
Foundation, and CASP-DFU) consisted of 1,649 PsA cases, 2,349
PsV cases, and 4,061 controls of white European ancestry from
the United States and Canada. Diagnosis of psoriasis was always
confirmed by a dermatologist. All PsA patients were diagnosed by a
rheumatologist and/or fulfilled CASPAR criteria for the classification
of PsA. All Candadian PsV patients underwent a rheumatological
examination to rule out the presence of inflammatory arthritis.
Patients with other forms of inflammatory arthritis were excluded.
Written, informed consent was obtained from all study partici-
pants, and all protocols were approved by the respective institutional
ethics review committees of the participating centers. The investiga-
tions were conducted according to the Declaration of Helsinki
Principles.
The samples were organized in panels, which corresponded to
the successive steps of the present study, and all panels (GWAS
panels and replication panels 1 through 6) were independent from
each other.
Genotyping
The genotyping for the German GWAS, which was part of the
German GWAS initiative funded by the National Genome Research
Network, was performed by Illumina’s service facility using the
Illumina HumanHap 550K v1 with 561,466 SNP markers (Illumina,
San Diego, CA). All experimental steps were carried out according to
the standard protocols. For genome-wide genotyping of the CASP
samples, the Perlegen 600k array was used (Perlegen Sciences,
Mountain View, CA). The genotyping was provided through the
Genetic Association Information Network. The Illumina Human 1M
BeadChip was used for generating the Canadian genome-wide data
(Genizon GWAS), as well as for genotypes of SNPs rs13017599 and
rs2829866 in replication panel 5 (CASP-DFU). Functionally tested
TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City,
CA) were used to genotype variants in replication panels 1 through 6.
Statistical analyses
We used GWAS data sets that passed stringent quality control filters
for genotype imputation with Beagle (Browning and Browning,
2009) using HapMap phase 3 reference samples from the CEU, TSI,
MEX, and GJT collections, as well as for the subsequent statistical
analyses. Low genomic-control values for all three scans (German
GWAS: lGC¼ 1.01, CASP GWAS: lGC¼ 1.02, and Canadian GWAS:
lGC¼ 1.03) indicated a minimal overall inflation of the test statistics
due to population stratification.
Power calculations were carried out using the PS Power and
Sample Size v3.0.12 (Dupont and Plummer, 1997; Supplementary
Figure S2 online). GWAS data were analyzed using R statistical
environment version 2.10.0 and gPLINK v2.049 in combination with
PLINK v1.05 (Purcell et al., 2007).
We selected 10 SNPs based on their P-value ranking for
replication in two independent samples from Germany and Estonia
comprising 252 PsA cases and 1,740 controls. All SNPs passed
quality control measures, which means that they had a high call rate
(495% in cases or controls), were not monomorphic (minor allele
frequency41% in cases or controls), and did not deviate from HWE
in the control population (exact HWE P4104). Two of the 10
follow-up SNPs were significantly associated with PsA and were
therefore genotyped in four additional replication panels from the
United States, Canada, and Estonia.
The Cochran–Mantel–Haenszel test was used for combined
replication analysis of replication panel 1 and 2 from Germany
and Estonia, to take the possibility of minor differing genetic
backgrounds into account. The initial GWAS meta-analysis was
performed using PLINK’s meta-analysis function with its standard
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Figure 2. Regional plot of the REL locus. Regional plot of the negative decadic logarithm of the combined P-values from the imputed meta-analysis
of three genome-wide association studies (GWAS). A window of 500 kb around the lead single-nucleotide polymorphism (SNP) rs13017599 (blue filled circle)
is shown. The three GWAS panels were imputed with CEU haplotypes generated by the 1,000 Genomes Project (August 2010 release) as a reference.
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error of OR weighting option. Association results of replication panel
5 (CASP-DFU) were obtained with the statistical association test
‘‘Efficient Mixed-Model Association eXpedited’’ to account for
sample structure (Kang et al., 2010), and the combined replication
analysis of all six replication panels, as well as the combined GWAS-
replication analysis, was performed with METAL (Willer et al.,
2010). Logistic regression analysis to test for the independence of the
two REL SNPs rs13017599 and rs702873 was performed with PLINK
using the conditional analysis commands logistic and condition to
test one SNP, but adding the allelic dosage for the other SNP as a
covariate. The conditional analysis was carried out for each cohort
separately and results were subsequently combined by means of
meta-analysis.
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